Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data

Telomir Pharmaceuticals, Inc. has announced new preclinical findings showcasing Telomir-1's ability to reverse DNA methylation of the CDKN2A gene, reactivating this key tumor suppressor often silenced in aggressive cancers. This breakthrough positions Telomir-1 as a potential first-in-class DNA methylation reset therapy.

CDKN2A is known for its role as a "cell cycle brake," crucial for stopping cell division and promoting apoptosis of damaged cells. Abnormal methylation often silences CDKN2A in cancers, allowing unchecked tumor growth. Telomir-1 successfully resets this methylation, possibly restoring its protective capacity.

In prostate cancer cell models, Telomir-1 outperformed Rapamycin and chemotherapy in inhibiting CDKN2A methylation. Telomir is advancing towards clinical trials, with additional studies exploring Telomir-1's efficacy in various cancers.